



Gavi/2014/088/ac

The Minister of National Health Regulation and Services.
Ministry of National Health regulation and Services
Government of Pakistan
Islamabad
Pakistan

19 December 2014

Dear Minister,

Management Letter: *Request for 2015 Renewal of Gavi support for new vaccines*

This management letter accompanies the Decision Letter about Pakistan's request for renewal for New Vaccines Support (NVS) for pentavalent and pneumococcal vaccines which were reviewed by the Gavi High Level Review Panel (HLRP) on 27-29 October 2014.

The HLRP replaces the monitoring Independent Review Committee in making recommendations to Gavi's Chief Executive Officer on the renewal of Gavi support for existing grants. This change is part of Gavi's new grant application, monitoring and review approach, which is designed to ensure closer coordination with countries' planning cycles, better align NVS and HSS support, and improve fiduciary oversight. The Review Panel, composed of Alliance partners and Independent Review Committee (IRC) members, is designed to increase the accountability of the Alliance, and to streamline the review processes. The Panel will meet several times a year to enable alignment with countries' budgetary and planning cycles.

Pakistan received a Partnership Framework Agreement (PFA) in June 2013. To date, we have not received the signatures of the Ministry of Health and Ministry of Finance on the PFA. Please be advised that until that Agreement has been signed between Gavi and Pakistan Gavi will not process any further applications (for HSS and new vaccine support) that the Independent Review Committee has recommended for approval and will no longer disburse subsequent tranches of Health System Strengthening and/or Immunisation Services Support funds that were approved earlier.

Please do not hesitate to contact me at acronin@gavi.org if you have any questions or concerns. I would be happy to set up a teleconference to discuss this further should this be required.



Yours sincerely,

A handwritten signature in blue ink that reads "Anne Cronin". The signature is written in a cursive style with a large initial 'A'.

Anne Cronin
Senior Country Manager, EMRO

Attachments: Pakistan's Internal Appraisal

cc: The Minister of Finance
 The Director of Medical Services
 Director Planning Unit, MoH
 The EPI Manager
 WHO Country Representative
 UNICEF Country Representative
 Regional Working Group
 WHO HQ
 UNICEF Programme Division
 The World Bank

Pakistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan			
2. Grant Number: 1115-PAK-12b-X			
3. Date of Decision Letter: 19/12/2014			
4. Date of the Partnership Framework Agreement: not yet signed			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2012 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2012-2014	2015	Total ²
Programme Budget (US\$)	US\$226,769,406 ³	US\$45,121,000	US\$271,890,406
10. Vaccine Introduction Grant: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ The Annual Amount for 2015 has been amended.

Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015
Number of Pneumococcal vaccines doses		10,891,600
Number of AD syringes		10,329,800
Number of re-constitution syringes		
Number of safety boxes		113,650
Annual Amounts (US\$)	US\$226,769,406 ⁵	US\$45,121,000

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1115-PAK-12b-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	1,200,000
Number of AD syringes	1,138,000
Number of re-constitution syringes	
Number of safety boxes	12,525
Value of vaccine doses (US\$)	US\$4,048,500
Total Co-Financing Payments (US\$) (including freight)	US\$4,232,500

15. Operational support for campaigns: Not applicable

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional documents to be delivered for future disbursements:


Reports, documents and other deliverables	Due dates
<i>Annual Progress Report 2014 or equivalent</i>	As agreed with the Gavi secretariat

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable.

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Not applicable.

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 December 2014

Pakistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

19. Country: Pakistan			
20. Grant Number: 1115-PAK-04a-X			
21. Date of Decision Letter: 19/12/2014			
22. Date of the Partnership Framework Agreement: not yet signed			
23. Programme Title: NVS, Pentavalent Routine			
24. Vaccine type: Pentavalent			
25. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
26. Programme Duration⁶: 2008 - 2015			
27. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2008-2014	2015	Total ⁷
Programme Budget (US\$)	US\$284,020,409 ⁸	US\$18,002,000	US\$302,022,409
28. Vaccine Introduction Grant: Not applicable			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.

29. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹ The Annual Amount for 2015 has been amended.

Type of supplies to be purchased with Gavi funds in each year	2008-2014	2015
Number of Pentavalent vaccines doses		8,843,400
Number of AD syringes		9,121,400
Number of re-constitution syringes		
Number of safety boxes		100,375
Annual Amounts (US\$)	US\$284,020,409 ¹⁰	US\$18,002,000

30. Procurement agency: UNICEF shall be the procurement agency for vaccines purchased with Gavi funding.

31. Self-procurement: Self-procurement applies to co-financed portion.

32. Co-financing obligations: Reference code: 1115-PAK-04a-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	2,581,900
Number of AD syringes	2,663,000
Number of re-constitution syringes	
Number of safety boxes	29,300
Value of vaccine doses (US\$)	US\$4,939,031
Total Co-Financing Payments (US\$) (including freight)	US\$5,256,000


33. Operational support for campaigns: Not applicable

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

34. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
<i>Annual Progress Report 2014 or equivalent</i>	As agreed with the Gavi Secretariat
35. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable. <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
36. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 December 2014